# MIMEDX GROUP, INC. (MDXG)

Informational only - not investment advice.

CIK: 0001376339
SIC: 3841 Surgical & Medical Instruments & Apparatus
SIC breadcrumb: [Manufacturing](/division/D/) > [SIC Major Group 38](/major-group/38/) > [SIC 3841 Surgical & Medical Instruments & Apparatus](/industry/3841/)
Latest 10-K filed: 2026-02-25
SEC page: https://www.sec.gov/edgar/browse/?CIK=1376339
Filing source: https://www.sec.gov/Archives/edgar/data/1376339/000137633926000011/mdxg-20251231.htm

## At a glance

FY2025 · period end 2025-12-31 · filed 2026-02-25 · accession 0001376339-26-000011 · source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001376339.json

| Metric | Value | FY | Provenance |
| --- | ---: | ---: | --- |
| Revenue | 418,630,000 USD | 2025 | verified |
| Net income | 48,578,000 USD | 2025 | verified |
| Assets | 342,653,000 USD | 2025 | verified |
| Net margin | 11.60% | 2025 | computed |
| Operating margin | 15.26% | 2025 | computed |
| Revenue YoY | +19.99% | 2025 | computed |
| ROE | 18.94% | 2025 | computed |

Computed values are grepcent-computed from the verified facts above and may differ from ratios the company itself reports. Net margin = net income ÷ revenue. Operating margin = operating income ÷ revenue. Revenue YoY = FY2025 revenue ÷ FY2024 revenue − 1 (consecutive fiscal years only). ROE = net income ÷ period-end stockholders' equity.

No market price, no rating, no forecast on this site. Not investment advice.

### Peer percentile fingerprint

| Ratio | MDXG | Peer median | Percentile | N |
| --- | ---: | ---: | ---: | ---: |
| Net margin | 11.6% | -6.0% | 76 | 63 |
| Operating margin | 15.3% | -2.7% | 76 | 63 |
| Revenue growth | 20.0% | 13.6% | 71 | 64 |
| ROE | 18.9% | -9.1% | 89 | 58 |
| ROA | 14.2% | -4.8% | 92 | 65 |
| Liabilities / equity | 0.34 | 0.89 | 24 | 63 |
| Current ratio | 4.32 | 3.23 | 61 | 65 |

Percentile = share of the N covered peers reporting that ratio whose value is lower (ties counted half); computed among grepcent-covered companies in SIC industry 3841 Surgical & Medical Instruments & Apparatus, not the whole market. A higher percentile means a higher value of the ratio, not a better company. Ratios with fewer than 8 reporting peers are omitted. Latest reported values per company; fiscal periods may differ. Descriptive arithmetic - not a score, rating, or ranking.

## Selected Fundamentals
| Metric | Value | Unit | FY | Filed |
| --- | ---: | --- | ---: | --- |
| Revenue | 418630000 | USD | 2025 | 2026-02-25 |
| Net income | 48578000 | USD | 2025 | 2026-02-25 |
| Assets | 342653000 | USD | 2025 | 2026-02-25 |

## Financials

Annual standardized facts from SEC companyfacts as of latest extracted filing date 2026-02-25. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001376339.json. Derived margins, ratios, and free cash flow are computed from the extracted annual SEC facts.

| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue |  | 221,712,000 | 321,139,000 | 359,111,000 | 299,255,000 | 248,234,000 | 242,019,000 | 267,841,000 | 321,477,000 | 348,879,000 | 418,630,000 |
| Net income |  | 390,000 | 64,727,000 | -29,979,000 | -25,580,000 | -49,284,000 | -10,285,000 | -30,197,000 | 58,228,000 | 42,419,000 | 48,578,000 |
| Operating income |  | 884,000 | 46,223,000 | -3,924,000 | -21,160,000 | -45,398,000 | -7,051,000 | -14,727,000 | 37,116,000 | 58,865,000 | 63,887,000 |
| Gross profit |  | 190,774,000 | 285,920,000 | 322,725,000 | 256,174,000 | 208,904,000 | 202,391,000 | 219,525,000 | 266,843,000 | 288,806,000 | 345,617,000 |
| Diluted EPS |  | 0.00 | 0.56 | -0.28 | -0.24 | -0.77 | -0.15 | -0.33 | 0.37 | 0.28 | 0.32 |
| Operating cash flow |  | 23,849,000 | 62,939,000 | 35,796,000 | -39,412,000 | -30,263,000 | -1,982,000 | -17,893,000 | 26,775,000 | 66,198,000 | 74,003,000 |
| Share buybacks | 40,143,000 | 10,400,000 | 68,300,000 | 7,600,000 |  | 900,000 | 0.00 | 0.00 | 9,515,000 | 0.00 | 0.00 |
| Assets |  | 117,274,000 | 121,255,000 | 122,844,000 | 167,166,000 | 202,032,000 | 187,929,000 | 171,430,000 | 239,047,000 | 263,915,000 | 342,653,000 |
| Liabilities |  | 69,207,000 | 47,458,000 | 73,189,000 | 132,768,000 | 110,614,000 | 95,353,000 | 96,924,000 | 96,330,000 | 70,808,000 | 86,105,000 |
| Stockholders' equity |  | 48,067,000 | 73,797,000 | 49,655,000 | 34,398,000 | -150,000 | 82,000 | -17,988,000 | 142,717,000 | 193,107,000 | 256,548,000 |
| Cash and cash equivalents |  | 30,321,000 | 27,476,000 | 45,118,000 | 69,069,000 | 95,812,000 | 87,083,000 | 65,950,000 | 82,000,000 | 104,416,000 | 166,121,000 |

### Ratios

ROE and ROA use period-end equity/assets. Liabilities / equity uses total liabilities divided by stockholders' equity. Current ratio uses current assets divided by current liabilities when both are reported.

| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Net margin |  | 0.18% | 20.16% | -8.35% | -8.55% | -19.85% | -4.25% | -11.27% | 18.11% | 12.16% | 11.60% |
| Operating margin |  | 0.40% | 14.39% | -1.09% | -7.07% | -18.29% | -2.91% | -5.50% | 11.55% | 16.87% | 15.26% |
| Return on equity |  | 0.81% | 87.71% | -60.37% | -74.36% |  |  |  | 40.80% | 21.97% | 18.94% |
| Return on assets |  | 0.33% | 53.38% | -24.40% | -15.30% | -24.39% | -5.47% | -17.61% | 24.36% | 16.07% | 14.18% |
| Liabilities / equity |  | 1.44 | 0.64 | 1.47 | 3.86 |  |  |  | 0.67 | 0.37 | 0.34 |
| Current ratio |  | 0.98 | 1.06 | 1.03 | 1.83 | 2.71 | 3.51 | 3.08 | 3.57 | 4.21 | 4.32 |

## As-reported value updates

12 tracked differences above grepcent's stated thresholds were found between the earliest XBRL-filed value and the value currently on file for the same fiscal period.

Ledger: /company/MDXG/revisions/


## Quarterly

Quarterly standardized facts from SEC companyfacts as of latest extracted filing date 2026-07-29. Source: https://data.sec.gov/api/xbrl/companyfacts/CIK0001376339.json.

Flow metrics use discrete quarter-length periods from 10-Q/10-Q/A filings. Q4 revenue and net income are derived only when annual FY and nine-month YTD facts exist for the same fiscal year; derived Q4 values are labeled. EPS Q4 is not derived.

| Quarter | End date | Revenue | Net income | Diluted EPS | Method |
| --- | --- | ---: | ---: | ---: | --- |
| 2022-Q3 | 2022-09-30 |  |  | -0.09 | reported discrete quarter |
| 2023-Q1 | 2023-03-31 |  |  | -0.06 | reported discrete quarter |
| 2023-Q2 | 2023-06-30 |  |  | 0.00 | reported discrete quarter |
| 2023-Q3 | 2023-09-30 | 81,712,000 | 8,534,000 | 0.06 | reported discrete quarter |
| 2023-Q4 | 2023-12-31 | 86,832,000 | 53,477,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2024-Q1 | 2024-03-31 | 84,709,000 | 9,261,000 | 0.06 | reported discrete quarter |
| 2024-Q2 | 2024-06-30 | 87,207,000 | 17,625,000 | 0.12 | reported discrete quarter |
| 2024-Q3 | 2024-09-30 | 84,057,000 | 8,095,000 | 0.05 | reported discrete quarter |
| 2024-Q4 | 2024-12-31 | 92,907,000 | 7,438,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2025-Q1 | 2025-03-31 | 88,205,000 | 7,023,000 | 0.05 | reported discrete quarter |
| 2025-Q2 | 2025-06-30 | 98,605,000 | 9,618,000 | 0.06 | reported discrete quarter |
| 2025-Q3 | 2025-09-30 | 113,725,000 | 16,748,000 | 0.11 | reported discrete quarter |
| 2025-Q4 | 2025-12-31 | 118,095,000 | 15,191,000 |  | derived Q4 = FY annual - nine-month YTD |
| 2026-Q1 | 2026-03-31 | 58,991,000 | -10,860,000 | -0.07 | reported discrete quarter |
| 2026-Q2 | 2026-06-30 | 64,362,000 | -14,840,000 | -0.10 | reported discrete quarter |

## Filed narrative (10-K & 10-Q)

## Business

Verbatim Item 1 Business section from MDXG's latest 10-K: [/company/MDXG/business/](/company/MDXG/business/).

## Risk Factors

Verbatim Item 1A Risk Factors from MDXG's latest 10-K: [/company/MDXG/risk-factors/](/company/MDXG/risk-factors/).

## Latest quarter (10-Q)

Latest 10-Q source: https://www.sec.gov/Archives/edgar/data/1376339/000137633926000071/mdxg-20260630.htm

Extracted structurally from real Item 2 body heading to real Item 3/4 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-07-29
Report date: 2026-06-30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

During the second quarter of 2026, we continued to execute our strategic priorities, including expanding our Surgical portfolio, launching new products, advancing recent cost reduction initiatives, and returning capital to shareholders through our Share Repurchase Plan. These efforts contributed to continued growth in the Surgical business, which demonstrated a sixth consecutive quarter of double-digit year-over-year growth.

•Net sales were $64 million, a decrease of 35% compared to the prior year period, driven by a 61% decline in Wound sales, partially offset by 15% growth in Surgical sales. Surgical growth was driven by continued adoption of AMNIOFIX®, AMNIOEFFECT®, and our particulate portfolio, as well as contributions from the Company’s distribution agreement with Summit Products Group, namely G4Derm® Plus.

•We reported a GAAP net loss of $15 million or $0.10 per diluted share, and ended the quarter with $136 million of cash and cash equivalents.

•During the quarter, we completed a reduction-in-force and implemented additional cost reduction initiatives designed to align our cost structure with current business needs and support operating efficiency.

•Separately, we repurchased approximately $13 million of common stock under our Share Repurchase Plan, reflecting our continued commitment to disciplined capital allocation and delivering long-term shareholder value.

Overview

MIMEDX is a pioneer and leader focused on helping humans heal. The Company has more than a decade and a half of experience developing and commercializing products used in the treatment of a wide range of Surgical and Wound management applications. All of our products sold in the United States are regulated by the U.S. Food & Drug Administration (“FDA”). We apply Current Good Tissue Practices (“CGTP”) and other applicable quality standards in addition to terminal sterilization to produce our allografts.

This discussion, which presents our results for the three and six months ended June 30, 2026 and 2025, should be read in conjunction with the unaudited condensed consolidated financial statements and accompanying notes included in this Form 10-Q and the financial statements and accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 filed with the SEC on February 25, 2026 (the “2025 Form 10-K”).

Results of Operations

Three Months Ended June 30, 2026 Compared to the Three Months Ended June 30, 2025

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,"],["","(in thousands)"],["","2026","","2025","","$ Change","","% Change"],["Net sales","$","64,362","","","$","98,605","","","$","(34,243)","","","(34.7)","%"],["Cost of sales","19,981","","","18,681","","","1,300","","","7.0","%"],["Gross profit","44,381","","","79,924","","","(35,543)","","","(44.5)","%"],["Selling, general and administrative","59,779","","","64,151","","","(4,372)","","","(6.8)","%"],["Research and development","2,777","","","3,303","","","(526)","","","(15.9)","%"],["Amortization of intangible assets","291","","","100","","","191","","","nm"],["Interest income, net","788","","","738","","","50","","","6.8","%"],["Other expense, net","(102)","","","(101)","","","(1)","","","1.0","%"],["Income tax provision benefit (expense)","2,940","","","(3,389)","","","6,329","","","nm"],["Net (loss) income","(14,840)","","","9,618","","","(24,458)","","","nm"]]
[[/GREPCENT_TABLE]]

Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.

19

Net Sales

Net sales were $64.4 million for the three months ended June 30, 2026, representing a decrease of $34.2 million, or 34.7%, compared to $98.6 million for the three months ended June 30, 2025.

Sales by product category were as follows (amounts in thousands):

[[GREPCENT_TABLE]]
[["","Three Months Ended June 30,","","Change"],["","2026","","2025","","$","","%"],["Surgical","$","39,297","","","$","34,129","","","$","5,168","","","15.1","%"],["Wound","25,065","","","64,476","","","(39,411)","","","(61.1)","%"],["Total","$","64,362","","","$","98,605","","","$","(34,243)","","","(34.7)","%"]]
[[/GREPCENT_TABLE]]

Surgical net sales were $39.3 million for the three months ended June 30, 2026, representing an increase of $5.2 million, or 15.1%, compared to $34.1 million for the three months ended June 30, 2025. This increase was primarily driven by continued growth in the AMNIOFIX and AMNIOEFFECT sheet products.

Wound net sales were $25.1 million for the three months ended June 30, 2026, representing a decrease of $39.4 million or 61.1%, compared to $64.5 million for the three months ended June 30, 2025. This decline was primarily driven by the continued impact of Medicare reimbursement changes effective January 1, 2026, which adversely affected both pricing and sales volumes for these products.

Cost of Sales and Gross Profit Margin

Cost of sales were $20.0 million for the three months ended June 30, 2026, representing an increase of $1.3 million, or 7.0%. compared to $18.7 million for the three months ended June 30, 2025. This increase was primarily driven by increased sales volume and one-time expenses related to our cost reduction initiative.

Gross profit margin was 69.0% for the three months ended June 30, 2026, compared to 81.1% for the three months ended June 30, 2025. This decline was primarily driven by lower pricing in the Wound business following the Medicare reimbursement changes and higher manufacturing costs.

Selling, General and Administrative Expense

Selling, general and administrative (“SG&A”) expense was $59.8 million for the three months ended June 30, 2026, compared to $64.2 million for the three months ended June 30, 2025. The following table shows the composition of this expense between selling and marketing (“S&M”) and general and administrative (“G&A”) components (amounts in thousands):

[[GREPCENT_TABLE]]
[["","","Three Months Ended June 30,","","Change"],["","","2026","","2025","","$","","%"],["Selling and marketing","","$","46,416","","","$","47,867","","","$","(1,451)","","","(3.0)","%"],["General and administrative","","13,363","","","16,284","","","(2,921)","","","(17.9)","%"],["Selling, general and administrative","","$","59,779","","","$","64,151","","","$","(4,372)","","","(6.8)","%"]]
[[/GREPCENT_TABLE]]

Sales and marketing expenses decreased $1.5 million or 3.0%, year over year, primarily driven by lower personnel, travel, and meeting expense resulting from our recent cost reduction initiative, as well as lower commission expense driven by reduced sales. These decreases were offset by bad debt expense, which increased $5.0 million, year over year. This increase is associated with the credit deterioration of certain legacy customers.

General and administrative expenses decreased $2.9 million or 17.9% year over year, primarily due to lower personnel expense resulting from our recent cost reduction initiative. This decrease was partially offset by increased legal expense associated with ongoing legal matters.

Research and Development Expense

Research and development (“R&D”) expense was $2.8 million for the three months ended June 30, 2026, representing a decrease of $0.5 million, or 15.9%, compared to $3.3 million for the three months ended June 30, 2025. This decrease was primarily driven by completion of patient activities in our EPIEFFECT study and the results of our cost reduction initiative. These impacts were offset by costs incurred toward our 510(k) submissions.

20

Interest Income, Net

Interest income, net was $0.8 million for the three months ended June 30, 2026, representing an increase of $0.1 million or 6.8% compared to $0.7 million for the three months ended June 30, 2025. The increase was driven by higher average cash balances maintained in the Company’s interest-bearing accounts and a reduction in outstanding debt. These impacts were offset by lower market interest rates.

Income Tax Provision

The effective tax rates for the Company were 16.5% and 26.1% for the three months ended June 30, 2026 and June 30, 2025, respectively.

Note that we generated pre-tax loss for the three months ended June 30, 2026, meaning that decreases in our effective tax rate would be unfavorable for that period. Conversely, we generated pre-tax income for the three months ended June 30, 2025, meaning that decreases in our effective tax rate would favorable for that period.

The effective tax rate for the three months ended June 30, 2026 was unfavorably impacted due to deduction limitations on executive compensation, in part resulting from one-time costs associated with our recent cost reduction initiative. Shortfall on restricted stock vestings further contributed to the unfavorability.

The effective tax rate for the three months ended June 30, 2025 was favorably impacted by windfall on restricted stock vestings. This was offset by deduction limitations on executive compensation.

Six Months Ended June 30, 2026 Compared to the Six Months Ended June 30, 2025

[[GREPCENT_TABLE]]
[["","Six Months Ended June 30,"],["","(in thousands)"],["","2026","","2025","","$ Change","","% Change"],["Net sales","$","123,353","","","$","186,810","","","$","(63,457)","","","(34.0)","%"],["Cost of sales","37,348","","","35,239","","","2,109","","","6.0","%"],["Gross profit","86,005","","","151,571","","","(65,566)","","","(43.3)","%"],["Selling, general and administrative","113,010","","","124,120","","","(11,110)","","","(9.0)","%"],["Research and development","6,917","","","6,632","","","285","","","4.3","%"],["Amortization of intangible assets","592","","","199","","","393","","","nm"],["Interest income, net","1,673","","","1,244","","","429","","","34.5","%"],["Other expense, net","(270)","","","(247)","","","(23)","","","9.3","%"],["Income tax provision benefit (expense)","7,411","","","(4,978)","","","12,389","","","nm"],["Net (loss) income","(25,700)","","","16,639","","","(42,339)","","","nm"]]
[[/GREPCENT_TABLE]]

Changes noted as “nm” in the table above indicate that the percentage change is not meaningful.

Net Sales

Net Sales were $123.4 million for the six months ended June 30, 2026, representing a decrease of $63.5 million, or 34.0%, compared to $186.8 million for the six months ended June 30, 2025.

Sales by product category were as follows (amounts in thousands):

[[GREPCENT_TABLE]]
[["","Six Months Ended June 30,","","Change"],["","2026","","2025","","$","","%"],["Surgical","$","75,671","","","$","66,261","","","$","9,410","","","14.2","%"],["Wound","47,682","","120,549","","(72,867)","","","(60.4)","%"],["Total","$","123,353","","","$","186,810","","","$","(63,457)","","","(34.0)","%"]]
[[/GREPCENT_TABLE]]

21

Surgical net sales were $75.7 million for the six months ended June 30, 2026, representing an increase of $9.4 million, or 14.2%, compared to the six months ended June 30, 2025. This increase was primarily driven by continued growth in the AMNIOFIX and AMNIOEFFECT sheet products.

Wound net sales were $47.7 million for the six months ended June 30, 2026, representing a decrease of 72.9 million or 60.4%, compared to the six months ended June 30, 2025. This decrease was primarily driven by the continued impact of Medicare reimbursement changes which adversely affected both pricing and sales volumes for these products.

Cost of Sales and Gross Profit Margin

Cost of sales were $37.3 million for the six months ended June 30, 2026, representing an increase of $2.1 million, or 6.0%, compared to $35.2 million for the six months ended June 30, 2025. This increase was primarily driven by increased sales volumes and one-time expenses related to our cost reduction initiative.

Gross profit margin was 69.7% for the six months ended June 30, 2026 compared to 81.1% for the six mo

[Excerpt truncated for page length; source filing is linked above.]

## Latest 10-K MD&A (excerpt)

Latest 10-K Item 7 source: https://www.sec.gov/Archives/edgar/data/1376339/000137633926000011/mdxg-20251231.htm
Complete FY 2025 MD&A: /company/MDXG/mda/fy2025/

Extracted structurally from real Item 7 body heading to real Item 7A/8 boundary. Published MD&A gate trimmed front/tail over-capture.
Confidence: high
Filing date: 2026-02-25
Report date: 2025-12-31

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Executive Summary

During 2025, we delivered 20.0% growth in net sales, with broad-based contributions across Wound and Surgical. This growth was driven by a combination of demand for newer Wound products (CELERA™, EMERGE™ and EPIXPRESS®), increasing adoption of Surgical products across a growing number of use cases in the operating room and commercial execution. Operating and financial highlights during the year include:

•Fourth quarter and full year 2025 net sales of $118.1 million and $418.6 million, respectively, reflecting 27.1% and 20.0% growth over the fourth quarter and full year 2024, respectively.

•GAAP net income for the fourth quarter and full year 2025 of $15.2 million and $48.6 million, respectively.

•Featured the Company’s growing body of clinical and scientific evidence at Wound & Surgical-focused industry conferences, including MedStar Georgetown University Hospital’s Diabetic Limb Salvage Conference, Symposium on Advanced Wound Care Spring and Fall meetings, and Digestive Disease Week 2025, among others.

•Announced publication of health economics data in Mohs micrographic surgery

•Entered into a strategic collaboration with Vaporox, Inc., establishing the ability for the Company to co-promote and co-market its leading placental allograft portfolio alongside Vaporox’s Vaporous Hyperoxia Treatment device

•Launched EPIXPRESS® the Company’s next-generation, lyophilized human placental allograft, further expanding the Company’s broad portfolio of advanced wound care products

•Announced interim results of its EPIEFFECT® randomized clinical trial, which were published and presented, demonstrating clinical benefit associated with use of EPIEFFECT® when compared to Standard of Care.

•Announced publication in the Journal of Inflammation focused on the immunomodulatory effects of Purion® processed human amniotic membrane allografts in vitro. The study, which investigated the influence of MIMEDX DHACM and LHACM products on inflammatory response, demonstrated support of the healing cascade and tissue repair.

•Entered into an exclusive U.S. distribution agreement for RegenKit®-Wound Gel with Regen Lab USA, LLC, continuing to broaden the Company’s leading Wound product offering beyond placental allografts.

Additionally, at the end of 2025, CMS finalized sweeping changes related to the reimbursement of skin substitutes, which were implemented on January 1, 2026. These changes include: 1) reimbursing skin substitute products uniformly across the HOPD and physician office and associated care settings and 2) capping the reimbursement rate for skin substitutes at $127.14 per square centimeter in these care settings, subject to geographic adjustments. The specific policies were put into effect in the Physician Fee Schedule (“PFS”) and Hospital Outpatient Prospective Payment System (“OPPS”).

Overview

MIMEDX is a pioneer and leader focused on helping humans heal. With nearly two decades of experience helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. All of our products sold in the United States are regulated by the U.S. Food and Drug Administration (“FDA”). We apply Current Good Tissue Practices (“CGTP”) and other applicable quality standards in addition to terminal sterilization to produce our allografts.

Recent Developments

On October 31, 2025, CMS issued the final update to Medicare reimbursement for skin substitutes, which was broadly in line with the initial proposed rate (the “2026 Rules”). Effective January 1, 2026, the 2026 Rules revolutionize skin substitute reimbursement by moving away from “Average Sales Price (ASP) +6%” model to a flat, standardized rate of $127.14 per square centimeter, cutting costs by nearly 90%. The change in policy to a flat rate is primarily driven to address skyrocketing expenditures – rising from ~$500 million in 2020 to ~$15 billion in 2025 (a nearly 40-fold increase) and to combat potential fraudulent billing, such as using larger-than-necessary grafts to maximize reimbursement.

The increased spending, proliferation of Q-coded skin substitute products, and higher ASPs for these products have been under increased regulatory scrutiny over the last couple of years. In response to these market dynamics, CMS announced the 2026 Rules related to the reimbursement of skin substitutes. The changes under the 2026 Rules include: 1) reimbursing skin

41

substitute products uniformly across the HOPD and physician office and associated care settings, 2) moving the reimbursement rate for skin substitutes from the “ASP+6%” methodology to a flat rate at $127.14 per square centimeter in these care settings, subject to geographic adjustments, and 3) reclassifying some products as “incident-to” supplies under the physician fee schedule and subject to a flat payment rate. This change applies to skin substitutes in three regulatory categories: (1) devices subject to premarket approval (PMA); (2) devices subject to 510(k) clearance; and (3) human cells, tissues and cellular and tissue-based products (HCT/Ps) regulated under Section 361 of the Public Health Service Act (the “PHS Act”). The 2026 Rules were put into effect in the Physician Fee Schedule (“PFS”) and Hospital Outpatient Prospective Payment System (“OPPS”).

While there are many unknowns of the 2026 Rules, we may need to tighten inventory management, to minimize losses from expired or unused products and also revisit pricing strategies in light of the new reimbursement model. As to how the 2026 Rules impact clinical practice and physician behavior, it will only become clear as implementation progresses. We anticipate that the 2026 Rules will be a headwind to both Advanced Wound Management sales and profitability in 2026, before any mitigating actions.

Our Products

Our product portfolio is divided into two categories (1) Wound and (2) Surgical.

Our Wound portfolio includes EPIFIX®, EPICORD®, EPIEFFECT®, EPIXPRESS®, CHORIOFIX™, EMERGE™, CELERA™, and RegenKit®-Wound Gel which are marketed for external use across a range of advanced wound applications. EMERGE™, CELERA™, and RegenKit®-Wound Gel are manufactured by third-party suppliers.

Our Surgical portfolio includes AMNIOFIX®, AMNIOEFFECT®, AMNIOBURN®, AMNIOCORD®, AXIOFILL®, and HELIOGEN™, which are marketed for use in diverse surgical applications, including lower extremity repair, plastic and reconstructive surgery, vascular procedures, and multiple orthopedic repairs. HELIOGEN™ is manufactured by third-party supplier Regenity Biosciences, Inc. Additionally, in early 2026 we began distributing three additional Surgical Products: G4Derm Plus, NovaForm and Hydrelix to further expand our Surgical product offering.

From time to time, we may acquire, manufacture, or market additional Wound or Surgical products in response to market demand or to maintain our competitive position.

This discussion, which presents our results for the fiscal years ended December 31, 2025 and 2024, should be read in conjunction with our Consolidated Financial Statements and the accompanying notes. Also, please refer to Part I, Item 1, Business, and Part I, Item 1A, Risk Factors, which include detailed discussions of various items impacting our business, results of operations and financial condition. We intend for this discussion to provide the reader with information that will assist in understanding our financial statements, the changes in certain key items in those financial statements from period to period and the primary factors that accounted for those changes. We also discuss certain performance metrics that management uses to assess the Company's performance.

Our Annual Report for the year ended December 31, 2024 (the “2024 Annual Report”) includes a discussion and analysis of our total company financial condition and results of operations for 2024 compared to 2023 in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Components of and Key Factors Influencing Our Results of Continuing Operations

In assessing the performance of our business, we consider a variety of performance and financial measures. We believe the items discussed below provide insight into the factors that affect these key measures.

Net sales

Our net sales are derived from selling our Wound and Surgical products to a wide range of customers, including hospitals, wound care centers and private physician offices that have clinicians using our suite of products to aid in the management of patients with chronic or hard-to-heal wounds. These customers choose products like ours based upon a variety of factors, including clinical efficacy, customer engagement programs, availability, handling characteristics, reimbursement coverage and payer sources.

Net sales are recognized based on the consideration we expect to receive from the sale at the point in time when control of the goods is transferred to the customer. For ship-and-bill sales, this occurs upon transfer of title to the customer. For consignment arrangements, this occurs upon implantation of the product on the end user . Net sales consists of the gross selling price of the product less any discounts, rebates and other customer incentives, fees paid to GPOs, and estimates for sales returns.

42

Cost of goods sold and gross profit

Cost of goods sold includes product testing costs, quality assurance costs, personnel costs, manufacturing costs, raw materials and product costs, depreciation, amortization of certain purchased assets and facility costs associated with our manufacturing and warehouse facilities. Fluctuations in our cost of goods sold correspond with the fluctuations in these costs as well as sales volume.

Gross profit is calculated as net sales less cost of goods sold. Gross margin is calculated as gross profit divided by net sales. Our gross margin is affected by product and geographic sales mix, realized pricing of our products, the efficiency of our manufacturing operations and the costs of materials used to make our products. Regulatory actions, including with respect to reimbursement for our products, may require costly expenditures or result in pricing pressure, and may decrease our gross profit and gross margin.

Selling, general and administrative expense

Selling, general and administrative expense consists of both selling and marketing (“S&M”) and general and administrative (“G&A”) expenses.

S&M expense includes costs to execute our sales strategy, which includes personnel costs pertaining to our sales force and sales support functions, including salaries, commissions and other incentive compensation, commissions to sales agents, customer support, travel expenses, and bad debt expense. We expect our S&M expense to fluctuate based on revenue fluctuations, geographic changes, and any changes to the size of our headcount, particularly that of our sales and marketing forces. Certain of these costs scale with sales, but can fluctuate depending on sales mix. For example, we pay sales agents a greater commission than our internal sales force, meaning that we could incur greater commission expenses if a greater proportion of our sales are through sales agents.

G&A expense reflects costs related to functions which support our business, such as legal, finance, human resources, and other such functions. This includes personnel costs associated with these functions, insurance, and certain professional fees. We expect our G&A expense to fluctuate based on headcount.

Research and development expense

Research and development expense relates to our investments to expand our product pipeline and platforms, including clinical trials as well as improvements to our manufacturing process and the enhancement of existing products. Our res

[Excerpt truncated for page length; the complete text is on the linked full-MD&A page.]

Read the full FY 2025 MD&A: /company/MDXG/mda/fy2025/
All MD&A years: /company/MDXG/mda/


## MD&A history

Prior-year 10-K MD&A spans are extracted from SEC filings with the same bounded parser used for the latest filing. Each year's full verbatim text is on its own sub-page.

- [FY 2024 MD&A](/company/MDXG/mda/fy2024/): filed 2025-02-26; accession 0001376339-25-000009 (https://www.sec.gov/Archives/edgar/data/1376339/000137633925000009/mdxg-20241231.htm)
- [FY 2023 MD&A](/company/MDXG/mda/fy2023/): filed 2024-02-28; accession 0001376339-24-000009 (https://www.sec.gov/Archives/edgar/data/1376339/000137633924000009/mdxg-20231231.htm)
- [FY 2022 MD&A](/company/MDXG/mda/fy2022/): filed 2023-02-28; accession 0001376339-23-000003 (https://www.sec.gov/Archives/edgar/data/1376339/000137633923000003/mdxg-20221231.htm)
- [FY 2021 MD&A](/company/MDXG/mda/fy2021/): filed 2022-02-28; accession 0001376339-22-000007 (https://www.sec.gov/Archives/edgar/data/1376339/000137633922000007/mdxg-20211231.htm)




## Macro cross-references

Indicators mapped to this company's SIC classification (industry 3841 Surgical & Medical Instruments & Apparatus) by grepcent's deterministic macro-sector crosswalk. A navigational mapping, not a statistical or causal claim.

- [INDPRO](/indicator/INDPRO/): Industrial Production: Total Index
- [TCU](/indicator/TCU/): Capacity Utilization: Total Index
- [PPIACO](/indicator/PPIACO/): Producer Price Index by Commodity: All Commodities
- [GDPC1](/indicator/GDPC1/): Real Gross Domestic Product
- [DGS10](/indicator/DGS10/): Market Yield on U.S. Treasury Securities at 10-Year Constant Maturity
- [FEDFUNDS](/indicator/FEDFUNDS/): Federal Funds Effective Rate
- [CES0500000003](/indicator/CES0500000003/): Average Hourly Earnings of All Employees, Total Private
- [PAYEMS](/indicator/PAYEMS/): All Employees, Total Nonfarm

Macro-to-micro threads including this sector: [Inflation (CPI / PCE / PPI)](/thread/inflation-cpi-pce-ppi/), [US labor market](/thread/us-labor-market/), [Growth & output](/thread/growth-output/), [Money & trade](/thread/money-trade/), [Government finances](/thread/government-finances/), [Sector employment](/thread/sector-employment/), [Industrial orders & inventories](/thread/industrial-orders/), [Trade & external](/thread/trade-external/).

All macro indicators: /indicators/


## For LLMs & downloads

Markdown twin: /company/MDXG.md · JSON record: /company/MDXG.json · verified financials: /company/MDXG/financials.json / /company/MDXG/financials.csv · machine TOC for the whole site: /llms.txt